An interventional study of Libre 3 Plus Continuous Glucose Monitor and Dexcom G7 Continuous Glucose Monitor in Type 2 Diabetes Mellitus (T2DM), Type 1 Diabetes Mellitus (T1DM) and Hyperglycemia, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Other
This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.
Exclusion Criteria:
Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.
Device: Libre 3 Plus Continuous Glucose Monitor
Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.
Device: Dexcom G7 Continuous Glucose Monitor
Subjects in this arm will start using the Libre 3 Plus continuous glucose monitor.
Subjects in this arm will start using the Dexcom G7 continuous glucose monitor.
Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system
Questionnaire responses regarding patient satisfaction and opinion regarding use of continuous glucose monitoring system: regarding how do subjects feel that using CGM impacted their glucose control on a scale of 1-5, with 1=strongly made it worse, 2=somewhat made it worse, 3=did not make it better or worse, 4=somewhat made it better, and 5=strongly made it better?; regarding what is the overall opinion of subject's experience with CGM use on a scale of 1-5, with 1=very negative, 2=negative, 3=neutral, 4=positive, 5=very positive.
Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes care
Questionnaire responses regarding patient satisfaction and opinion regarding quality of diabetes care: regarding how do subjects feel that using CGM impacted the diabetes care overall on a scale of 1-5, with 1=strongly made it worse, 2=somewhat made it worse, 3=did not make it better or worse, 4=somewhat made it better, and 5=strongly made it better.
Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Questionnaire responses regarding patient familiarity with continuous glucose monitoring
Questionnaire responses regarding patient familiarity with continuous glucose monitoring: regarding degree of familiarity of CGMs in general and the different types of information provided by CGMs, what is the subject's familiarity on a scale of 1-5, with 1=very unfamiliar, 2=unfamiliar, 3=neutral, 4=familiar, 5=very familiar.
Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Degree of Average Change in Hemoglobin A1C from Start to End of Study
Degree of average change in Hemoglobin A1C from start to end of study
Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Degree of Average Change in Glucose Management Indicator (GMI)
Degree of average change in glucose management indicator (GMI)
Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Number of Participants with 30-day Readmissions Related to Glycemic Control
Number of participants with 30-day Readmissions Related to Glycemic Control (hyperglycemia, hypoglycemia, or diabetic ketoacidosis)
Time frame: From enrollment until follow-up telephone visit 2-3 weeks after discharge
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center